65 results about "Vaccinia" patented technology

Provided herein is a method for efficiently capping RNA in vitro. In some embodiments the capping reaction may be done at high temperature using Vaccinia capping enzyme or a variant thereof. In other embodiments, the capping reactions may comprise a capping enzyme from a large virus of amoeba, e.g., Faustovirus, mimivirus or moumouvirus, or a variant thereof. Compositions and kits for practicing the method are also provided.

The present invention relates to a primer set, composition, kit for the detection of vaccinia virus for the detection and quantification of vaccinia virus and an analysis method using the same, and the primer set for the detection of vaccinia virus has a shorter analysis period and superior sensitivity and specificity compared to the conventional virus quantitation method, so that when real-time PCR applied to such a primer set is performed, it is possible to detect and quantify vaccinia virus more quickly and accurately in real time.

The invention relates to the technical field of biomedical engineering. The invention provides an application of an oncolytic vaccinia virus carrying a stritin interference sequence in an anti-tumor drug, a stritin inhibitor recombinant vector, an application of the stritin inhibitor recombinant vector in preparation of the anti-tumor drug, and an anti-tumor drug composition taking a stritin inhibitor or the stritin inhibitor recombinant vector as an active component. According to the present invention, the inhibition on the Stritin can be used for preparing the anti-tumor virus drug, and particularly the recombinant vector is formed by recombining the Stritin inhibitor and the vaccinia virus, such that the advantages of the Stritin inhibitor and the vaccinia virus can be combined, the new target spot is provided for the tumor virus treatment, and the broad clinical application prospect is provided.

Exemplary methods, compositions, kits and uses thereof for treating neoplasia are provided. For example, a method can be provided for treating neoplasia in a subject, including administering to the subject a VRK2 (vaccinia-related kinase 2) inhibitor, alone or in combination with an inhibitor of Programmed cell death receptor-1 (PD-1). The exemplary methods, compositions and kits may improve cancer immunotherapy.

This invention provides a vaccinia virus that induces cell fusion between infected cells and a method for producing the same. Such vaccinia virus is deprived of the K2L gene or the HA gene or functions of the K2L gene and the HA gene and is mutated to induce cell fusion between infected cells and induce cell death.

The use of extract from rabbit skin inflamed by vaccinia virus for treating Parkinson's disease or restoring neurological function of the brain or alleviating damage to neurological function of the brain in a patient suffering from Parkinson's disease is provided. The extract from rabbit skin inflamed by vaccinia virus can be Lepalvir.

The present invention relates to an oncolytic vaccinia virus and viral vectors for use in the treatment of cancer wherein the virus consists of at least three vaccinia virus promoters positioned in the same orientation.

Described herein are methods and compositions for treating a disease, e.g. cancer (including solid tumors), using glial cells (e.g. microglia cells and / or astrocytes) and / or macrophages (e.g., CNS-associated macrophages) infected with an oncolytic virus (e.g., vaccinia virus). The methods and compositions provided herein demonstrate a synergistic anti-cancer effect.

Provided herein is a method for efficiently capping RNA in vitro. In some embodiments the capping reaction may be done at high temperature using Vaccinia capping enzyme or a variant thereof. In other embodiments, the capping reactions may comprise a capping enzyme from a large virus of amoeba, e.g., Faustovirus, mimivirus or moumouvirus, or a variant thereof. Compositions and kits for practicing the method are also provided.

This invention relates to the fields of biotechnology and targeted therapy, specifically to a recombinant construct, a recombinant oncolytic virus, its construction method, and its applications. The recombinant oncolytic virus CD19 BIKE is prepared by inserting exogenous genes for CD16 and CD19 into the genome of an oncolytic vaccinia virus. The antibodies secreted by this recombinant virus can not only bridge NK cells and CD19-positive B-cell lymphoma cells, increasing the contact between NK cells and tumor cells and their accumulation within tumor tissue, but also synergize with the tumor-lysing effect of the oncolytic virus, breaking down the stromal barrier, reshaping the tumor microenvironment, and enhancing therapeutic efficacy.

Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (Burkholderia pseudomallei, Borrelia burgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Francisella tularensis, human Herpes virus 1 and 2, Mycobacterium tuberculosis, Plasmodium falciparum, and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.

The present invention relates to the therapeutic use of extract from rabbit skin inflamed by vaccinia virus. More specifically, the present invention relates to the use of extract from rabbit skin inflamed by vaccinia virus for treating Alzheimer's disease. In addition, the present invention relates to the use of extract from rabbit skin inflamed by vaccinia virus for protecting neurological function of the brain or alleviating damage to neurological function of the brain in a patient suffering from Alzheimer's disease. In addition, the extract from rabbit skin inflamed by vaccinia virus can be Lepalvir.

The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising vaccinia virus and hydroxyurea as active ingredients. The pharmaceutical composition for treating cancer, comprising vaccinia virus and hydroxyurea as active ingredients according to the present invention, exhibits a higher anti-cancer effect and safety than conventional vaccinia virus alone administration. Therefore, the pharmaceutical composition comprising vaccinia virus and hydroxyurea as active ingredients according to the present invention can be advantageously used for treating cancer.

The present invention provides compositions, vaccines, and methods for inducing protective immunity to immunogens in humans. Protective immune responses are obtained by using saRNA, particularly VRP vectors as a prime and MVA vectors for boosting. Specifically, the present invention relates to genetically engineered (recombinant) VRP and MVA vectors that contain at least one heterologous nucleotide sequence encoding an antigenic determinant of an infectious virus (e.g., EBV).

Disclosed herein are method of vaccinating or treating a subject for a hepatitis C virus. In certain embodiments, methods comprise administering to a subject a DNA plasmid encoding hepatitis C virus core, E1, E2, and / or p7 proteins. In certain embodiments, methods further comprise administering a recombinant attenuated vaccinia vector encoding hepatitis C virus non-structural NS3, NS4a, NS4b, NS5a and / or NS5b proteins. In certain embodiments, the subject is a human subject.

To provide a method for efficiently capping RNA in vitro.SOLUTION: In some embodiments, the capping reaction can be done at high temperature using Vaccinia capping enzyme or variants thereof. In other embodiments, the capping reaction may comprise capping enzymes from amoebic large viruses, such as Faust, Mimivirus, or Moumouvirus, or variants thereof. Compositions and kits for practicing the methods are also provided.SELECTED DRAWING: None

The invention belongs to the field of clinical technology, and provides preparation and clinical application of growth differentiation factor 11 (GDF11) mRNA for promoting wound healing, and the preparation method comprises the following steps: S1, carrying out N1 psi modification on GDF11 mRNA, and replacing uracil in an original sequence with N1 psi; s2, synthesizing the modified GDF11 mRNA (messenger Ribonucleic Acid); s3, purifying the synthesized GDF11 mRNA (messenger Ribonucleic Acid), so as to obtain mRNA with modified nucleoside; by optimizing the preparation method of growth differentiation factor 11 (GDF11) mRNA, the preparation method comprises the following steps: performing N1 psi modification, synthesizing by adopting a vaccinia enzyme m capping 7G capping system, adding a poly (A) tail, purifying, and wrapping in lipid nanoparticles (LNP) to form a stable delivery system, so that the stability and translation efficiency of mRNA are remarkably improved, and the stability and translation efficiency of the GDF11 are remarkably improved. And the defects existing in treatment by directly using the GDF11 protein in the prior art are overcome, an efficient and safe new strategy is provided for diabetes wound treatment, and remarkable beneficial effects are achieved.

Provided herein is a method for efficiently capping RNA in vitro. In some embodiments the capping reaction may be done at high temperature using Vaccinia capping enzyme or a variant thereof. In other embodiments, the capping reactions may comprise a capping enzyme from a large virus of amoeba, e.g., Faustovirus, mimivirus or moumouvirus, or a variant thereof. Compositions and kits for practicing the method are also provided.

The invention belongs to the technical field of biological medicines, and provides a heat stress protein HSP70 inhibitor and application thereof in preparation of antitumor drugs. Experiments prove that the heat stress protein HSP70 inhibitor can enhance the replication capacity of oncolytic viruses in tumor cells and enhance the anti-tumor immune activation capacity at the same time; the invention further proves that the oncoVV-shHSP70 can effectively inhibit the expression of the HSP70 protein, so that the survival rate of various cancer cells can be obviously reduced, the effect is obviously superior to that of a control virus oncoVV only lacking the TK gene, and meanwhile, the oncoVV-shHSP70 can promote the infiltration of CD8 < + >-T cells in tumor tissues. The HSP70 inhibitor can be used for preparing an anti-tumor virus drug, particularly, the HSP70 inhibitor and the vaccinia virus are recombined into a recombinant vector, the advantages of the HSP70 inhibitor and the vaccinia virus can be combined, a new target spot is provided for virus treatment of tumors, and the HSP70 inhibitor has a wide clinical application prospect.

Exemplary methods, compositions, kits and uses thereof for treating neoplasia are provided. For example, a method can be provided for treating neoplasia in a subject, including administering to the subject a VRK2 (vaccinia-related kinase 2) inhibitor, alone or in combination with an inhibitor of Programmed cell death receptor-1 (PD-1). The exemplary methods, compositions and kits may improve cancer immunotherapy.

The present invention relates to the use of an extract derived from rabbit skin inflamed by vaccinia virus in treatment. More specifically, the present invention relates to the use of an extract derived from rabbit skin inflamed by vaccinia virus in treatment of hematopoietic system damage or pancytopenia induced by cancer therapy. Furthermore, the present invention relates to the use of an extract derived from rabbit skin inflamed by vaccinia virus in treatment of leukopenia induced by cancer therapy. Furthermore, the extract derived from rabbit skin inflamed by vaccinia virus may be suitable for regeneration.

The present invention relates to recombinant Modified Vaccina Virus Ankara (MVA) encoding Epstein-Barr virus (EBV) antigens, wherein surface glycoprotein 350 (EBV gp350) and glycoprotein gH (EBV gH) are fused to subunits of self-assembling multimeric protein particle PdhC (acetyltransferase of pyruvate dehydrogenase (PDH) complex) or DPS (DNA binding protein from starved cells).

The present invention provides genetically modified vaccinia virus which may be employed as an oncolytic viral vector, wherein the genetically modified vaccinia virus comprises a nucleic acid molecule encoding a modified matrix protein from a vesicular stomatitis virus and wherein the genetically modified vaccinia virus is fusogenic.

To provide newly adapted and / or more potent viruses and / or virus vectors useful for treatment of human diseases.SOLUTION: Disclosed herein is a novel immune-modulating vaccinia virus strain (IOVA) and derivatives thereof with high replication efficiency for use in the medicine. The novel vaccinia virus strain IOVA and derivatives thereof, vectors and recombinants have an ability to replicate in a mammal cancer line and being lytic or, in the case of cancer cells, oncolytic, and elicit an increased capacity to destroy cell-cycle activated cells and / or tumor cells, compared with the gold standard Vaccinia virus WR.SELECTED DRAWING: None

There is provided a method of treating chronic hepatitis B infection (CHB) and / or chronic hepatitis D infection (CHD) in a human, comprising the steps of:a) administering to the human a composition comprising an antisense oligonucleotide (ASO) 10 to 30 nucleosides in length, targeted to a HBV nucleic acid (an HBV ASO);b) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc);c) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); andd) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.

The present invention relates to recombinant modified vaccinia virus Ankara (MVA) encoding the spike (S) protein or portions thereof, such as the receptor binding domain (RBD), and additional antigenic sequences derived from other proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 19 (COVID-19).

The invention relates to the technical field of heat preservation boxes, in particular to vaccinia virus seed collecting and transporting equipment which comprises a box body, a support and a protective cover, a sealing plate is arranged on the box body, a sealing cover is movably connected to the box body, a protective assembly is arranged in the sealing cover, the support is arranged in the box body, and mounting blocks are arranged at the front end, the rear end, the left end and the right end of the support. During use, vaccine test tubes are conveniently fixed through the arranged fixing assembly, damage caused by shaking and collision of the vaccine test tubes in the box body is avoided, then a pull rod is pulled to drive a sliding block, a supporting plate and a protective cover to move upwards, and the matched supporting assembly supports the sliding block and the supporting plate which ascend; and then a sealing cover is covered, and the arranged protection assembly is tightly attached to the top of the vaccine test tube, so that the vaccine test tube is prevented from shaking up and down, and the protection effect on the vaccine test tube is further improved.

The disclosure provides recombinant vaccinia vectors (rVACV) comprising variant A34R proteins. As compared to a vaccinia vector comprising the wild-type A34R protein, the rVACVs described herein exhibit increased production of extra-cellular enveloped virion (EEV). Also described herein are variant A34R proteins, nucleic acids encoding variant A34R proteins, and cells containing the nucleic acids encoding variant A34R proteins. The disclosure further provides methods of producing rVACV by culturing the cells containing the nucleic acids encoding variant A34R proteins and purifying the rVACV. Furthermore, provided are methods of treating a cancer in a subject by administering to the subject rVACVs comprising the variant A34R proteins.

The invention relates to the field of biotechnology and targeted therapy, in particular to a recombinant construct, a recombinant oncolytic virus and a construction method and application of the recombinant oncolytic virus. The recombinant oncolytic virus CD19 BIKE is prepared by inserting exogenous genes of CD16 and CD19 into an oncolytic vaccinia virus genome. The antibody secreted by the recombinant virus not only can bridge NK cells and CD19 positive B cell lymphoma cells to increase contact between the NK cells and tumor cells and accumulation in tumor tissues, but also can cooperate with oncolytic viruses to dissolve tumors, break matrix barriers, remodel tumor microenvironments and improve treatment effects.

The invention belongs to the technical field of mRNA vaccine preparation, and particularly relates to a helicobacter pylori infection resistant mRNA vaccine and application thereof. A UreB antigen sequence is optimized through AI calculation, a sequence is synthesized through a gene synthesis technology after optimization, the mRNA vaccine for resisting helicobacter pylori infection is obtained through T7 in-vitro transcription, a vaccinia capping system and a lithium chloride purification mode, the mRNA vaccine can induce a body to generate T lymphocyte immune response and high-titer UreB specific antibody humoral immune response, and the helicobacter pylori infection resisting mRNA vaccine can be used for resisting helicobacter pylori infection. The composition can be used for preventing helicobacter pylori infection related diseases.